A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK - PubMed (original) (raw)

A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK

A D Hingorani et al. Circulation. 1999.

Abstract

Background: Endothelium-derived nitric oxide (NO) is synthesised from L-arginine by endothelial nitric oxide synthase (eNOS) encoded by the NOS 3 gene on chromosome 7. Because reduced NO synthesis has been implicated in the development of coronary atherosclerosis, which has a heritable component, we hypothesised that polymorphisms of NOS 3 might be associated with increased susceptibility to this disorder.

Methods and results: Single-strand conformation polymorphism analysis of NOS 3 identified a G-->T polymorphism in exon 7 of the gene which encodes a Glu-->Asp amino acid substitution at residue 298 of eNOS. We investigated the relationship between this Glu(298)-->Asp variant and atherosclerotic coronary artery disease (CAD) using 2 independent case-controlled studies. In the first study (CHAOS), cases consisted of 298 unrelated patients with positive coronary angiograms and controls were 138 unrelated healthy individuals ascertained through a population health screen. In the second study (CHAOS II), the cases were 249 patients with recent myocardial infarction (MI), and a further 183 unrelated controls. There was an excess of homozygotes for the Asp298 variant among patients with angiographic CAD, and among patients with recent MI when compared with their respective controls (35.9% versus 10.2%, P<0.0001 in CHAOS, and 18.1% versus 8.7%, P<0.02 in CHAOS II). In comparison to Glu(298) homozygotes, homozygosity for Asp(298) was associated with an odds ratio of 4.2 (95% CI, 2.3 to 7.9) for angiographic CAD and 2.5 (95% CI, 1.3 to 4.2) for MI.

Conclusions: Homozygosity for a common NOS 3 polymorphism (894 G-->T) which encodes a Glu298-->Asp amino acid substitution in eNOS is a risk factor for angiographic CAD and recent MI in this population.

PubMed Disclaimer

Cited by

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL. Casadei Gardini A, et al. Oncotarget. 2016 May 10;7(19):27988-99. doi: 10.18632/oncotarget.8569. Oncotarget. 2016. PMID: 27058899 Free PMC article.
A common variant of endothelial nitric oxide synthase (Glu298Asp) is associated with collateral development in patients with chronic coronary occlusions.
Lamblin N, Cuilleret FJ, Helbecque N, Dallongeville J, Lablanche JM, Amouyel P, Bauters C, Van Belle E. Lamblin N, et al. BMC Cardiovasc Disord. 2005 Sep 15;5:27. doi: 10.1186/1471-2261-5-27. BMC Cardiovasc Disord. 2005. PMID: 16164743 Free PMC article.
Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk.
Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar SM, Bao X, Rana BK, Smith DW, Wessel J, Salem RM, Rodriguez-Flores JL, Mahata SK, Schork NJ, Ziegler MG, O'Connor DT. Zhang L, et al. J Clin Invest. 2007 Sep;117(9):2658-71. doi: 10.1172/JCI31093. J Clin Invest. 2007. PMID: 17717598 Free PMC article.
Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298-->Asp polymorphism) to the presence, extent, and severity of coronary artery disease.
Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Masetti S, Rossi G, Clerico A, Biagini A. Colombo MG, et al. Heart. 2002 Jun;87(6):525-8. doi: 10.1136/heart.87.6.525. Heart. 2002. PMID: 12010932 Free PMC article.
Dysregulated insulin secretion is associated with pancreatic β-cell hyperplasia and direct acinar-β-cell trans-differentiation in partially eNOS-deficient mice.
Novelli M, Masini M, Vecoli C, Moscato S, Funel N, Pippa A, Mattii L, Ippolito C, Campani D, Neglia D, Masiello P. Novelli M, et al. Physiol Rep. 2022 Aug;10(16):e15425. doi: 10.14814/phy2.15425. Physiol Rep. 2022. PMID: 35986504 Free PMC article.

A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK - PubMed (original) (raw)